THOUSAND OAKS, Calif., Apr 11, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced that it plans to report its
first quarter financial results on Monday, April 23, 2007 after the
close of the financial markets. The announcement will be followed by a
conference call with the investment community at 2 p.m. Pacific Time.
Participating in the call from Amgen will be Kevin Sharer, chairman
and chief executive officer, and other members of Amgen´s senior
The Company initially planned to report first quarter earnings on
April 19 but has postponed the announcement until April 23 to include
the top line results of the Aranesp(R) (darbepoetin alfa) 145 study in
small cell lung cancer patients receiving chemotherapy.
Live audio of the conference call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the general public. The conference call, including the
question and answer session, is expected to last approximately one
The webcast of the conference, as with other selected
presentations regarding developments in Amgen´s business given by
management at certain investor and medical conferences, can be found
on Amgen´s Web site, www.amgen.com, under Investors. Information
regarding presentation times, webcast availability, and webcast links
are noted on Amgen´s Investor Relations Events Calendar. The webcast
will be archived and available for replay 72 hours after the event.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
John Shutter, 805-447-1060 (investors)